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Available online 15 November 2014An effective vaccine against human immunodeficiency virus type 1 (HIV-1) will have to provide
protection against a vast array of different HIV-1 strains. Current methods to measure HIV-1-
specific binding antibodies following immunization typically focus on determining themagnitude
of antibody responses, but the epitope diversity of antibody responses has remained largely
unexplored. Here we describe the development of a global HIV-1 peptide microarray that
contains 6564 peptides from across the HIV-1 proteome and covers the majority of HIV-1
sequences in the Los Alamos National Laboratory global HIV-1 sequence database. Using this
microarray, we quantified the magnitude, breadth, and depth of IgG binding to linear HIV-1
sequences in HIV-1-infected humans and HIV-1-vaccinated humans, rhesus monkeys and guinea
pigs. The microarray measured potentially important differences in antibody epitope diversity,
particularly regarding the depth of epitope variants recognized at each binding site. Our data
suggest that the global HIV-1 peptide microarray may be a useful tool for both preclinical and
clinical HIV-1 research.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).Keywords:
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Vaccine1 . Introduction
One of the fundamental challenges in HIV-1 vaccine
development is the tremendous diversity of HIV-1 strains
worldwide (Korber et al., 2001; Gaschen et al., 2002; Taylor
et al., 2008; Barouch and Korber, 2009; Korber et al., 2009;
Walker et al., 2011; Ndung'u and Weiss, 2012; Picker et al.,
2012; Stephenson and Barouch, 2013). Globally, there aremore
than a dozen HIV-1 subtypes and hundreds of circulatingHIV-1accine Research, Beth
e, E/CLS-1047, Boston,
1 617 735 4566.
Barouch).
ics Research, Cologne,
.V. This is an open access articrecombinant forms (CRFs), and between-subtype variation can
be as large as 35% (Hemelaar et al., 2006; Taylor et al., 2008;
Ndung'u and Weiss, 2012). Several HIV-1 vaccine candidates
under development aim to overcome the challenge of HIV-1
genetic diversity either through the choice of HIV-1 antigen
sequence or the method of antigen delivery (Stephenson and
Barouch, 2013). However, most tools used to assess the
immunogenicity of these vaccines focus on measuring the
magnitude of HIV-1-specific antibody responses, rather than
the epitope diversity and specificity of these responses.
Peptide microarrays are a potential tool for the measure-
ment of antibody diversity against linear epitopes in HIV-1
vaccine studies. This platform has been utilized to characterize
antibody binding to linear sequences in multiple fields,
including HIV-1 vaccine research (Nahtman et al., 2007;le under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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2009; Tomaras et al., 2011; Haynes et al., 2012). HIV-1-specific
microarrays to date, however, have not included extensive
coverage of variable sequences (Karasavvas et al., 2012;
Gottardo et al., 2013; Imholte et al., 2013). Here we describe
the development of a global HIV-1 peptide microarray that
includes 6564 overlapping linear HIV-1 peptides coveringmost
common HIV-1 variants in the HIV-1 sequence database at Los
Alamos National Laboratory (LANL). This microarray includes
6564 peptides, including an average of 7 peptide variants for
each 15 amino acid position in HIV-1 Env, Gag, Nef, Pol, Rev,
Tat, and Vif, with up to 95 peptide variants per location within
the most variable regions of HIV-1 Env. This epitope diversity
on themicroarray allows formore precisemeasurements of the
magnitude, breadth and depth of HIV-1-specific linear binding
IgG responses.
2 . Methods
2.1. Generation of peptide library
In collaboration with JPT Peptide Technologies (Berlin,
Germany), we designed a library of HIV-1 linear peptides that
provided optimal coverage of HIV-1 global sequence diversity.
We began by downloading the sequence alignment for HIV-1
genes ENV, GAG, NEF, POL, REV, TAT, and VIF from the website
of the LANL HIV-1 sequence database (Kuiken et al., 2009)
using the following settings: Alignment type: Web Alignment
(all complete sequences); Year: 2009; Region: Pre-defined
region of the genome; Subtype: All M Group (A–K +
Recombinants); DNA/Protein: Protein; Format: FASTA. Full
length proteins of gp120, gp41, p17, p24, Tat, and Nef wereTable 1
Composition of global HIV-1 peptide microarray.
Gene Position HXB2 start Position HXB2 end Protein
ENV 1 511 gp160_1
512 856 gp160_2
GAG 1 132 p17
133 363 p24
364 379 p2p7p1p6_1
380 394 p2p7p1p6_2
406 420 p2p7p1p6_3
428 450 p2p7p1p6_4
NEF 1 205 Nef
POL 57 71 Prot_1
97 104 Prot_2
217 231 RT_1
402 420 RT_2
447 461 RT_3
500 514 RT_4
529 543 RT_5
594 608 RT_6
673 707 RT_7
716 774 Int_1
865 879 Int_2
924 990 Int_3
REV 3 17 Rev_1
32 50 Rev_2
70 116 Rev_3
TAT 1 100 Tat
VIF 33 47 Vif_1
174 192 Vif_2used, as were the immunogenic fragments of p2p7p1p6,
protease, reverse transcriptase, integrase, Vif, and Ref as
published by LANL (Theoretical Biology and Biophysics, 2010)
(Table 1).
From the global sequence database, we selected the
individual sequences to be used as peptides that would provide
optimal coverage of sequence diversity using the program
package MosaicVaccines.1.2.11 from LANL (ftp://ftp-t10.lanl.
gov/pub/btk/mosaic/) (Fischer et al., 2007; Thurmond et al.,
2008). Parameters for the generation of MOSAIC sequences
were –s 20 –d=true –T 20 –p 100. Sequencemanipulation and
processing were performed in R 2.11.1 (http://www.r-project.
org/) using the package Biostrings (http:www.bioconductor.
org/packages/2.2/bioc/html/Biostrings.html) or using bespoke
scripts in python (http:www.python.org/).
Since our goal was to cover the seven most frequent clades
(A, B, C, D, G, CRF01_AE, and CRF02_AG), we used a stepwise
approach to generate an optimal sequence cocktail. As a first
step, the MOSAIC program was used to identify a sequence
for each gene product or fragment from each of the 7 most
frequent clades, and the resulting 7 sequences were merged
into one cocktail. Secondly, we identified 13 additional
sequences which showed best coverage without consideration
of the clade. These two sequence cocktails were merged into
one cocktail and evaluated for gain of coverage for each
sequence. All sequences which did not gain more than 0.75%
of coverage were removed from the cocktail. Thirdly, MOSAIC
sequences were generated for each gene product or fragment,
respectively (Fischer et al., 2007; Thurmond et al., 2008). For
the MOSAIC runs the sequence cocktails generated in the
previous step were used as fixed sequences. The resulting
cocktails were evaluated in terms of coverage gain. All MOSAIC# of input sequences # Peptides on array Global coverage [%]
2248 2672 50.2
2248 1210 65.5
3578 517 58.4
3578 264 86.2
3578 20 10.5
3578 18 17.9
3578 13 71.7
3577 50 68.7
2606 667 55.3
1765 10 88.4
1765 13 75.4
1765 4 90.5
1765 8 69.3
1765 13 51.4
1765 14 86.1
1765 22 84.9
1765 17 52
1765 51 41.5
1765 98 40
1765 16 70.3
1765 68 81.3
1370 17 26.1
1370 14 78.3
1370 187 42.6
1286 296 55.5
1643 19 9.8
1642 38 38.7
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and a maximum of 2 MOSAIC sequences was kept in the
final cocktail. Fig. 1A displays the relationship between the
increasing size of the cocktail and the plateauing increase in
coverage for gp120 and p24.
Oncewehad generated a cocktail of sequenceswith optimal
global coverage, we then generated a library of peptides where
all sequences within the cocktail were covered at a minimal
number of peptides. One of the sequences was used as a
template sequence and processed into 15 amino acid peptides
overlapping by 11 amino acids. All other sequences within the
cocktail were fragmented into peptide scans of 15 amino acid
peptides overlapping by 14 amino acids. Of note, this length of
peptide (15 amino acids) covers 83% of known linear antibody
epitopes in the LANL immunology database, including the
median length of epitopes (11 amino acids) (Theoretical
Biology and Biophysics, 2014). Scan-peptides were then
aligned onto the scan-peptides of the template. The resulting
5141 peptides covered all template sequences completely. For
ENV, we performed one additional step to assure that every
region of the protein was represented on the microarray by
adding additional MOSAIC sequences that our group generated
in the course of HIV-1 vaccine design (Barouch et al., 2010,
2013). To overcome the bias of peptides towards conserved
regions of the protein, we also included an additional 1004
peptides from the variable loops V2 and V3 of gp120 in the
library.Fig. 1. Generation of a global HIV-1 peptide library. (A) Cocktail size of Env gp120 a
variability. The cocktails consist of the single best covering sequences from each of the
calculated from the complete HIV-1 sequence library andMOSAIC sequences (right of v
sets are shown. Only sets that have N300 peptides are shown out of a total of 135 sets.
multiple sets.The final library consisted of 6564 peptides from 135
different clades or CRFs. CRFs are circulating related variants
that have different regions associated with the different major
HIV-1 clades (Robertson et al., 2000); for example CRF_02 has
sections of clade A and clade G, and is common in West Africa.
(For a comprehensive listing of CRF's see http://www.hiv.lanl.
gov/content/sequence/HIV/CRFs/CRFs.html). By capturing A
clade diversity, we capture some of the diversity found in the
regions of CRF_02 that are A-like, but CRF_02 started with a
recombinant founder virus decades ago, and has been spread-
ing and diversifying as a separate lineage (Zhang et al., 2010),
and so it will have its own distinctive evolutionary trajectory.
Each CRF represents its own lineage, thus by including the CRFs
in diversity considerations, not just major clades, we take a
more comprehensive and realistic view of global diversity than
by a more narrow examination of major clades. Fig. 1B shows
how many peptides were included in each clade- or CRF-
specific peptide set (only sets that contain N300 peptides are
shown). If a peptide sequence was found in multiple clades/
CRFs, then it was counted in multiple sets. Peptide set from the
seven most frequent clades (A, B, C, D, G, CRF_01, and CRF_02)
include N500 peptides each.
2.2. Microarray printing
PepStar peptide microarrays were produced by JPT
Peptide Technologies GmbH (Berlin, Germany). All peptidesnd Gag p24 sequences is plotted against percent coverage of global sequence
7 frequent clades (left of vertical line), and the 13 best covering sequences as
ertical line). (B) Clade- and circulating recombinant form (CRF)-specific peptide
If a peptide sequence was found in multiple clades/CRFs, then it was counted in
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sis technology. Subsequent to a final synthesis step attaching a
reactivity tag to each peptide's N-terminus, the side chains
were deprotected and the solid-phase bound peptides were
transferred into 96-well microtiter filtration plates (Millipore,
Bedford,MA, USA). For cleaving the peptides from the cellulose
membrane the individual spots were treated with aqueous
triethylamine [2.5% (v/v)]. The peptide-containing solution
was centrifuge-filtered into daughter plates and the solvent
was removed by evaporation under reduced pressure. Quality
controlmeasurements using LCMSwere performed on random
samples of the final library. For transferring the peptides to 384
well plates, the dry peptide derivatives were dissolved in 35 μL
of printing buffer and reformatted with automated liquid
handling systems. Peptide microarrays were produced using a
non-contact high performance microarray printer on epoxy-
modified slides (PolyAn; Germany). All peptides and controls
were deposited in three identical sub-arrays, enabling analysis
of assay homogeneity and reliability of the results. Peptide
microarrays were scanned after printing process and statistical
values were generated for identification and quality control of
each individual spot. Subsequently, peptide microarray sur-
faces were deactivated using appropriate quenching solutions,
washed with water and dried using microarray centrifuges.
Resulting peptide microarrays were stored at 4 °C until use.
2.3. Sample selection
Thirty-six (36) serum or plasma samples were obtained
from previously performed studies in the Barouch laboratory
and were selected to represent a spectrum of potential
preclinical and clinical uses for the microarray. Samples
included (a) plasma from 5 HIV-1-infected individuals from
North Americawith high HIV-1 viral load and 5HIV-uninfected
controls, (b) serum from5 human subjects vaccinatedwith one
dose of adenovirus 26 (Ad26) vaccine expressing clade A HIV-1
Env and 5 naive human controls, (c) serum from 5 rhesus
monkeys vaccinated with 6 doses of clade C HIV-1 Env protein
and 2 naïvemonkey controls, and (d) serum from 5 guinea pigs
vaccinated with 6 doses of clade C HIV-1 Env protein and 3
naïve guinea pig controls.
2.4. Microarray incubation and immunolabeling
Microarray slides were incubated with serum or plasma
using the manual method, essentially as described (Masch
et al., 2010). Serum or plasma was diluted 1/200 in SuperBlock
T20 (TBS) Blocking Buffer (Thermo Scientific). Slides were
placed in the individual chambers of a Sarstedt Quadriperm
Dish and incubated in 4 mL of diluted serum/plasma for 1 h
at 30 °C. Slides were then washed with 5 mL of TBS-Buffer +
0.1%Tween20 for 3 min on a shaker at room temperature
for 5 washes. Next, slides were incubated with Alexa Fluor
647-conjugated AffiniPure Mouse Anti-Human IgG (H + L)
(Jackson ImmunoResearch Laboratories) for human or
monkey samples for 1 h in the dark on a shaker at room
temperature. Alexa Fluor 647-conjugated AffiniPure Goat
Anti-Guinea Pig IgG (H + L) (Jackson ImmunoResearch
Laboratories) was used for guinea pig samples. Slides were
then washed 5 times with TBS-Buffer with 0.1%Tween20,
and 5 times with deionized water. To dry, slides were placedin a 50 mL conical and spun at 1500 rpm for 5 min. Of note,
all batches of slides were run in parallel with a control slide
that is incubated with secondary antibody alone.
2.5. Microarray image analysis
Slides were scanned with a GenePix 4300A scanner
(Molecular Devices), using 635 nm and 532 nm lasers at
500 PMT and 100 Power settings. Images were saved as TIF
files. The fluorescent intensity for each feature (peptide spot)
was calculated using GenePix Pro 7 software and GenePix
Array List (GAL) file, a text file with specific information about
the location, size, and name of each feature on the slide. This
analysis created a GenePix Results (GPR) file. We then
calculated the mean fluorescent intensity across the triplicate
sub-arrays (SAs) for each feature; if the coefficient of variation
was greater than 0.5, then the mean of the two closest values
was used. These calculations were performed with a custom-
designed R script “MakeDat_V04” (available as Appendix 1)
and R software package 2.15.2. Data was saved as a comma-
delimited DAT file usable by Excel (Microsoft). MakeDat_V04
also created scatterplots of the correlation between the feature
fluorescent intensities of sub-arrays 1 and 2, sub-arrays 2 and 3,
and sub-arrays 1 and 3 as a measure of assay quality (Fig. 3).
The threshold value used to define a minimum positive
fluorescent intensity was calculated for each slide using the
computational tool rapmad (Robust Alignment of Peptide
MicroArray Data, available for free at http://tron-mainz.de/
tron-facilities/computational-medicine/compmed) and the
custom-designed R script “calc_THRES_KS_130711_V02”
(available as Appendix 2). This analysis is based on the
method as previously described (Renard et al., 2011) and
distinguishes those peptide features that carry a signal from
those features that only display noise. Data from each
individual slide was combined with data from the control
slide to create two distributions of data (noise and signal).
We then calculated four potential threshold values for
positivity with increasing levels of stringency: the false
discovery rate cutoff (FDR cutoff), the point at which the
chance that signal is noise is P b 0.01, 5 standard deviations
above the mean of the noise distribution (SD.noise*5), and
the point at which the chance that signal is noise is very low
at P b 10−16.
2.6. Analysis ofmagnitude, breadth, and depth of antibody binding
The raw magnitude, or fluorescent intensity, of antibody
binding to individual peptides (averaged over the 3 sub-arrays
as described above) was sorted and categorized by (1) HIV-1
protein, (2) amino acid start position as aligned to HXB2 HIV-1
reference strain, and (3) HIV-1 clade or CRF within which the
peptide sequence can be found. This sorting was performed
using the custom-designed R script “Table_select_V01” (avail-
able as Appendix 3). To correct for any direct binding of the
secondary antibody to linear peptides, the fluorescent intensity
of antibody binding measured on the control slide was
subtracted from the fluorescent intensity of antibody binding
measured on the sample slide. Finally, all corrected fluorescent
intensities were compared to the calculated threshold for
positivity, and all values above the threshold were considered
positive (with the rest of the values changed to “0” and
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SD.noise*5.
To calculate the breadth of antibody binding, we evaluated
the number of positive peptides for each sample and aligned
the peptide sequences to eliminate overlap. If any positive
peptide sequences shared 5 or more contiguous amino acids,
we assumed that the peptides were recognized by the same
antigen-binding site on a single antibody; these overlapping
sequences were conservatively defined as a single positive
“binding site.” If the first and last overlappingpeptide in a string
of overlapping peptides shared 4 or less amino acids, we
assumed that the peptides were recognized by a minimum of
two antibody sites (on either two antibodies or the same
antibody). This approach to calculating antibody breadth is
based on established methods to calculate T cell breadth,
essentially as described in (Stephenson et al., 2012). The
primary difference is that the overlapping region for T cells is
usually 9 or more amino acids, reflecting the structure of CD4/
CD8 T cell binding pockets. For antibodies, the antigen-binding
site can range in length, and for conformational epitopes may
not be contiguous. For this analysis, 5 amino acids was chosen
as the minimum overlap region for antibody binding based on
the fact that, apart from ahandful of 3 and 4AA sequences, 5 AA
is theminimum length reported for human antibody binding to
linear HIV-1 sequences as per the LANL HIV Immunology
Database (Theoretical Biology and Biophysics, 2014). Confor-
mational epitopes cannot be directly assessed with linear
peptide microarray.
To calculate the depth of antibody responses, we evaluated
the overlapping sequences of each binding site and determined
the number of unique sequence variations of the binding site
that were present. We then calculated the average number ofFig. 2. Coverage of HIV-1 peptide library for gp120 by clade. Top row: A, C, G, CRF02_AG
represents the sequence of gp120. Sequences segments included on themicroarray are
alignmentHIV1_ALL_2009_ENV_PRO.fasta are shown (total 2248). The average coverag
was performed presuming the same length of all sequences for one protein or fragmevariations/binding site for each sample. We also determined
the relative frequency of clade or CRF-specific antibody
responses. To do this we first defined distinct clade or CRF
peptide ‘sets’ that included any peptide whose sequence had
been identified in that clade or CRF (see Fig. 1B). If a sequence
could be found across multiple clades, it was included in
multiple sets. We then calculated the percent of positive
peptides within each set to provide a relative measure of
clade- or CRF-specific antibody responses that could be
comparable across sets of different sizes. To maximize our
ability to detect differences in clade- or CRF-specific antibody
responses, we restricted this analysis to the variable regions V1
V2 and V3 of gp120.
3 . Results and discussion
3.1. Evaluation of coverage of global HIV-1 sequence diversity
In designing this microarray, our goal was to develop a
tool to measure the diversity of HIV-1-specific antibody
binding to linear HIV-1 epitopes from global sequences. To
determine how well the peptide library represented global
HIV-1 sequence diversity, we analyzed coverage using the
program package MosaicVaccines.1.2.11 as described above.
We found that the peptide library covered the majority of
sequences in the Los Alamos National Laboratory Database
(Table 1), including gp120 (50.2%), gp41 (65.5%), Gag p17
(58.4%), and Gag p24 (86.2%). Of note, for some protein regions
a small group of 15-mer peptides sufficed to span a reported
antibody binding site, but because the site was of high
sequence diversity with no conserved sequences, the observed
coverage was low (e.g. VIF_1 with 9% coverage reported).; bottom row: B, D, CRF01_AE, and all other clades. The X-direction of each plot
depicted in red. In the Y-direction all sequences for the respective clade from the
e (horizontally) for eachusedHIV-1 sequence is 50%. The evaluation of coverage
nt within a given clade.
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clades A, B, C, D, G, CRF01_AE, CRF02_AG, and a summary
population of all other clades (Fig. 2). This analysis demon-
strated that for each clade- or CRF-specific sequence, 50% of the
sequence (on average) was covered by peptides on the
microarray. As expected, in the variable regions of the HIV-1
proteome lower coverage was achieved, as for the variable
loops in ENV V1/V2 (HXB2 131–196) or V4 (HXB2 385–418).
However, the microarray reached a maximum of 95 peptide
variants for each location within the most variable regions of
HIV-1 Env, and an average of 7 peptide variants for each
location on HIV-1 Env, Gag, Nef, Pol, Rev, Tat, and Vif.
The diversity of linear peptides on the global HIV-1
microarray described here is in contrast to the composition of
the predominant HIV-1 peptide microarray previously report-
ed in the literature (Tomaras et al., 2011; Karasavvas et al.,
2012; Gottardo et al., 2013; Imholte et al., 2013). This previous
microarray includes gp160 subtype consensus sequences from
sixHIV-1 groupMsubtypes (A, B, C, D, CRF_01 andCRF_02) and
a consensus group M gp160, Con-S. In contrast to the global
microarray reported here, this previous microarray contains
less than a quarter of the number of peptides (1423 vs. 6564),Fig. 3. Quality analysis of raw microarray data. The signal distribution of a representat
This data is following incubation with serum from an HIV-1-infected subject. SA, sub-a
values between the 3 sub-arrays; MC2 1 and MC2 2, each component of MC2.excludes variable sequences by design, and does not include
any non-Env proteins, making it potentially less optimal for
quantifying HIV-1 antibody epitope diversity.
3.2. Evaluation of microarray assay quality and determination of
threshold values for positivity
Given the density of peptides on the microarray (19,692
peptides over 3 triplicate sub-arrays), we designed a program
to evaluate the quality of rawmicroarray data following sample
incubation and immunolabeling, as described above. Fig. 3
demonstrates representative results of this analysis following
microarray incubation with plasma from an HIV-1-infected
subject. As shown in this example, the program provides a
snapshot of how well the results from each sub-array correlate
with each other; in this case the correlation ranged from R2 =
0.93 to 0.96. We also designed a program to determine a
threshold value above which a signal can be considered
“positive” (Renard et al., 2011). Fig. 4 demonstrates representa-
tive results of this analysis when the microarray was incubated
with plasma from an HIV-1-infected subject. By providing four
potential threshold values with varying stringency, the programive microarray is displayed, as well as the correlation between slide sub-arrays.
rray; Rq, R squared; Sl, slope; In, intersection with the y axis; MC2, two closest
Fig. 4. Determination of threshold values for positivity. The signal and noise distribution of data from a sample microarray are displayed, as well as the
correlation between slide sub-arrays. Microarray data is following incubation with plasma from an HIV-1-infected subject. FDR, false discovery rate; SD,
standard deviation.
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greater sensitivity or specificity in detecting antibody binding.
3.3. Quantitating and visualizing antibody binding diversity
The goal of this project was to develop a method to both
quantitate and visualize antibody binding patterns to diverse
HIV-1 sequences for the purpose of HIV-1 vaccine and
therapeutic research. To visualize binding patterns, one can
plot the magnitude of peptide binding (MFI) by peptide
location (starting amino acid position). For instance, Fig. 5A
demonstrates the gp140-specific binding pattern among HIV-
1-infected subjects, where the average MFI per peptide is
shown for the 5 subjects. In this example, peakMFI valueswere
observed at the V3 region of gp120 and the CC loop region of
gp41, with maximum values about 60,000MFI, consistent with
well-described immunodominant regions in HIV-1 infection
(Goudsmit, 1988; Tomaras et al., 2008; Tomaras and Haynes,
2009; McMichael et al., 2010). Among HIV-uninfected controls,
there were a handful of nonspecific positive peptides, but peak
values did not rise above 4500 MFI (Fig. 5B). For comparison,
Fig. 5C shows the binding pattern among human subjects
vaccinated with a single priming dose of Ad26-EnvA HIV-1
vaccine. Here peak binding values were observed to V1, V2 and
V3 linear peptides, with maximum MFIs up to about 12,000.
The lower MFI of vaccinees compared to HIV-1-infected
subjects is expected given receipt of only one dose of vaccine
without subsequent boosting, but were still above those
observed in naïve controls (Fig. 5D). Of note, sera from naïve
controls demonstratedmore nonspecific positive peptides than
plasma from naïve controls.
As shown in Fig. 5E–H, the peptide microarray can also be
used to map antibody binding patterns in two animal models
commonly used in HIV-1 vaccine research: rhesus macaquesand guinea pigs (Nkolola et al., 2010; Barouch et al., 2012,
2013; Nkolola et al., 2014). In both examples, animals were
vaccinated with 6 serial doses of clade C HIV-1 protein and
developed a similar binding pattern, with peak responses at V3.
ThehigherMFIs among vaccinated animals compared tohumans
are likely due to the increased number of boosts received by the
animals. Of note, naïve guinea pig samples demonstrated higher
backgrounds than naïve human or monkey samples.
While maps of antibody binding can provide a useful tool
to visualize binding patterns, they are less useful for the
quantitative comparison of groups or HIV-1 regions. To provide
such quantitative data, we calculated the average MFI of peptide
binding sorted by region and HIV-1 protein (Fig. 6A);magnitude
can be compared across subjects or vaccine platforms as long as
the dilution factor for the assay is kept constant, as was done in
these experiments. As demonstrated in Fig. 6A, the microarray
can help characterize which regions of the HIV-1 envelope are
preferentially targeted. For example, in HIV-1-infected subjects,
V3-specific binding was significantly greater than to any other
gp120 region (P b 0.02 for all comparisons by t-test) and CC
loop-specific binding was greater than to any other gp41 region
(P b 0.002 for all comparisons by t-test). In contrast, human
vaccinees did not showa preference for V3 or CC loop responses,
although the vaccine included these antigens.
It is also useful to know whether HIV-1-specific antibodies
are binding to a limited region of the HIV-1 envelope or if
multiple areas are targeted. Fig. 6B demonstrates the number of
binding sites (“breadth”) by gp120 and gp41 region for our four
groups of samples. Here, we can see that while the vaccinated
human subjects had relatively low magnitude gp140 binding
compared to HIV-1-infected subjects, there was no discernable
difference in antibody breadth between the two groups.
This ability to distinguish between magnitude and breadth
is important in HIV-1 vaccine research. For example, if a
Fig. 5. IgG binding to linear HIV-1 gp140 peptides in HIV-1-infected subjects and vaccine recipients. The mean fluorescent intensity (MFI) of positive HIV-1 gp140
peptides is plotted against the amino acid start position as aligned to HXB2 HIV-1 reference strain for (A) 5 HIV-1-infected human subjects with high viral load, (B) 5
HIV-uninfected plasma controls, (C) 5 human subjects following one dose of Ad26-EnvA HIV-1 vaccine, (D) 5 naïve human serum controls, (E) 5 rhesus monkeys
following 6 doses of HIV-1 Clade C Env protein, (F) 2 naïve rhesusmonkey serum controls, (G) 5 guinea pigs following 6 doses of HIV-1 Clade C Env protein, and (H) 3
naïve guinea pig serum controls. Symbols represent the average MFI from infected or vaccinated subjects (color squares) and controls (black circles); bars represent
SEM.
112 K.E. Stephenson et al. / Journal of Immunological Methods 416 (2015) 105–123
113K.E. Stephenson et al. / Journal of Immunological Methods 416 (2015) 105–123particular vaccine candidate elicits lowmagnitude but broad
antibody responses, then one might decide to change the
vaccine vector or schedule to boost responses. On the other
hand, if the vaccine candidate elicits high magnitude but
narrow antibody responses, then one might decide to retain
the same vector and schedule, but change the immunogen to
broaden the specificity.
We also developed the microarray to measure the cross-
clade binding of HIV-1-specific antibodies. Fig. 6C demonstrates
themean number of epitope variants per binding site by gp120
and gp41 region for the four groups of samples. This analysis
shows that the Ad26-EnvA vaccine elicited comparable depth
of V4 binding as seen in the HIV-1-infected subjects (5 vs. 6
variants/binding site, P = NS by t-test), even though the
vaccine elicited significantly lower magnitude of V4 binding
(1955 vs. 10,468 MFI, P = 0.0031 by t-test). In addition, the
depth of V2 binding among vaccinated guinea pigs could not be
predicted by magnitude alone. For example, while HIV-1-
infected humans and HIV-1-vaccinated guinea pigs had the
same magnitude of V2-specific responses (5998 vs. 7770 MFI,
P = NS by t-test), the vaccinated guinea pigs had significantly
greater depth of V2-specific binding (7 vs. 20 variants/binding
site, P = 0.0161 by t-test). Despite substantial differences in
the human and guinea pig studies, this example demonstrates
how the microarray can discriminate between magnitude and
depth of antibody responses. This information may be highly
relevant to HIV-1 vaccine researchers who aim to design a
global HIV-1 vaccine capable of blocking acquisition of diverse
HIV-1 strains.Fig. 6. Magnitude, breadth, and depth of HIV-1-specific antibody binding, as measure
plotted by gp120 and gp41 region, including (A) themean fluorescent intensity of posit
mean number of epitope variants at each binding site (depth). The four groups includ
rhesus monkeys (green), and vaccinated guinea pigs (purple). Bars represent SEM.We also calculated the relative clade- or CRF-specific
binding present for the three most frequent clades (A, B, and
C). Fig. 7 demonstrates the percent of each clade- or CRF-
specific peptide set that was positive for the four groupswithin
the variable regions V1V2 and V3. In Fig. 7A, we can see that
among vaccinated monkeys and guinea pigs, V1V2-specific
responses were increased compared to the other cohorts, and
that binding to clades A and C V1V2 peptides predominated,
whereas clade B-specific binding was relatively low. This
finding likely reflects the fact that both monkeys and guinea
pigs received clade C Env immunogens. In contrast, in Fig. 7B,
we can see that among HIV-1-infected subjects, who had
increased V3-specific responses, binding to clade B peptides
predominated. This finding presumably reflects the fact that
these subjects were from North America and were infected
with clade B HIV-1. These data suggest that the microarray
may not only be useful for measuring cross-clade immune
responses following vaccination, but also may have an
application in serotyping HIV-1-infected subjects. Further
studies with larger numbers of HIV-1-infected subjects from
different regions could test this hypothesis.
Finally, we also designed the microarray to assess HIV-1-
specific binding across the HIV-1 proteome. In Fig. 8A, we
demonstrate the magnitude, breadth, and depth of HIV-1-
specific binding to gp120, gp41, Gag, Nef, Pol, Rev, Tat, and Vif
proteins among5HIV-1-infected human subjects.We observed
that gp41 (which includes regions from the cytoplasmic tail)
has the highest binding magnitude, followed by Gag. Fig. 8B
shows the antibody binding pattern for Gag among 5 HIV-1-d by global HIV-1 peptide microarray. Antibody responses for four groups are
ive peptides (magnitude), (B) the number of binding sites (breadth), and (C) the
e HIV-1-infected subjects (blue), vaccinated human subjects (red), vaccinated
Fig. 7. Cross-clade HIV-1 antibody binding as measured by global HIV-1 peptide
microarray. The percent of clade- or CRF-specific peptide sets that are positive for
V1V2 and V3 regions of gp120. The four cohorts include HIV-1-infected subjects
(blue), vaccinated human subjects (red), vaccinated rhesusmonkeys (green), and
vaccinated guinea pigs (purple). Bars represent SEM.
Fig. 8. IgG binding to linear HIV-1 peptides from across the HIV-1 proteome in HIV-1
peptides (magnitude), number of binding sites (breadth), andmean variants per bindin
subjects. Bars represent SEM. In addition, the MFI of positive HIV-1 Gag peptides are p
strain for 5 HIV-1-infected human subjects (B) and 5 HIV-uninfected controls (C). Bar
114 K.E. Stephenson et al. / Journal of Immunological Methods 416 (2015) 105–123infected subjects; peak values are noted within the p17 region,
with very little Gag-specific binding among naïve controls
(Fig. 8C). Antibody binding to non-Env proteins may be relevant
to evaluate vaccine potency and for certain non-neutralizing
antibodies (Lewis, 2014). Some studies have also shown an
association between anti-p24 responses and virologic control
(Weber et al., 1987; Trkola et al., 2004). In addition, the
microarray might be useful to assess vaccine-induced
seroreactivity in the context of HIV-1 vaccine clinical trials.
4 . Conclusions
As more HIV-1 vaccine candidates progress into clinical
trials, it is important to develop new tools to assess the epitope
diversity of HIV-1-specific antibodies. Here we report the
development of a global HIV-1 peptide microarray based on a
library of 6564 peptides covering the majority of sequences in
the Los Alamos National Laboratory HIV-1 sequence database.
This microarray provides a method to measure the magnitude,
breadth, and depth of IgG binding to linear HIV-1 peptides,
allowing for a more in depth analysis of antibody epitope
diversity than is currently available. Such knowledge may
contribute to improvements in HIV-1 vaccine design and
development, or to a better understanding of immune
responses to HIV-1 infection. The major limitations are that
this assay does not measure conformational antibodies or
antibody function. Nevertheless, when used in conjunction
with other antibody assays, themicroarray assays should prove
useful for both preclinical and clinical HIV-1 research.
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